Full-Time

Scientist – Technology Development

Posted on 1/27/2025

Alamar Biosciences

Alamar Biosciences

51-200 employees

Develops technology for protein detection and analysis

Biotechnology
Healthcare

Compensation Overview

$125k - $150kAnnually

+ Bonus + Equity

Mid, Senior

Fremont, CA, USA

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis

You match the following Alamar Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD degree in Biochemistry, Molecular Biology, or related field; OR MS degree with 3 years of industrial experience
  • 2+ years of hands-on experience running ELISA, qPCR, or similar
  • A demonstrated ability to follow SOPs and document results
  • Strong organizational skills
  • Strong communication skills to work within a multidisciplinary team environment
Responsibilities
  • Design and execute experiments to develop multiplex biomarker assays
  • Apply laboratory skills and experience to generate high-quality data in developing new technologies and new biomarker assays
  • Maintain accurate records of work performed, including reagents, methodology, and results. Perform data analysis and report results
  • Examine the impacts of multiple variables on assay performance and perform troubleshooting as needed
  • Support in-house engineers to integrate and adapt different assay workflows onto Alamar’s proprietary instrument platform
Desired Qualifications
  • Experience in developing multiplex assays is desirable
  • Experience in automation or in using automated liquid handlers is a plus
  • Experience in IVD product development with ELISA immunoassay and/or NGS is a plus
  • Self-motivation with a positive “can do” attitude, attention to detail, and ability to manage complex projects are critical
  • Data management skills are highly desired

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments. Alamar's ARGO™ system complements NULISA™ by providing a fully automated platform for high-throughput precision proteomics, enabling users to analyze multiple protein targets in a single experiment. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it accessible to a broader range of clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options for various diseases.

Company Size

51-200

Company Stage

Grant

Total Funding

$225.7M

Headquarters

Hayward, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Alamar's expansion into the APAC region enhances its global commercial presence.
  • The $10M investment for Alzheimer's diagnostics boosts Alamar's precision medicine capabilities.
  • Collaboration with The Michael J. Fox Foundation advances Parkinson's research and biomarker discovery.

What critics are saying

  • Emerging competition from companies like Olink Proteomics could challenge Alamar's market position.
  • Potential regulatory hurdles in the APAC region may delay ARGO™ HT System deployment.
  • High development costs of proteomics technology could strain Alamar's financial resources.

What makes Alamar Biosciences unique

  • Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection and measurement.
  • The ARGO™ system provides a fully automated, high-throughput precision proteomics platform.
  • NULISAseq™ Inflammation Panel AQ sets a new standard in immune response profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

7%
PR Newswire
Jan 22nd, 2025
Alamar Biosciences Presenta Nulisaseq Inflammation Panel Aq

Una herramienta revolucionaria que permite la cuantificación integral de la respuesta inmune en cohortes clínicas. FREMONT, Calif., 22 de enero de 2025 /PRNewswire/ -- Alamar Biosciences, una empresa que impulsa la proteómica de precisión para permitir la detección temprana de enfermedades, se enorgullece de anunciar el lanzamiento de NULISAseq™ Inflammation Panel AQ, que establece un nuevo estándar en la elaboración de perfiles de la respuesta inmunitaria en estudios clínicos o longitudinales. Diseñado para ofrecer una cobertura y precisión incomparables, el NULISAseq Inflammation Panel AQ permite a los investigadores descubrir nuevas características de la progresión de la enfermedad o la respuesta terapéutica con mediciones cuantitativas absolutas de más de 150 biomarcadores proteicos clave a partir de una sola muestra. Con una sensibilidad excepcional, el NULISAseq Inflammation Panel AQ permite la detección de niveles de citocinas tanto en estados normales como patológicos, lo que proporciona una plataforma sólida para el seguimiento de los cambios inmunitarios desde el inicio o después de intervenciones terapéuticas en cohortes clínicas. Esta solución transformadora redefine la precisión en el descubrimiento de biomarcadores y la investigación clínica

PR Newswire
Jan 22nd, 2025
Alamar Biosciences Unveils Nulisaseq Inflammation Panel Aq

Revolutionary tool enables comprehensive quantitation of immune response in clinical cohorts.FREMONT, Calif., Jan. 22, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq™ Inflammation Panel AQ, setting a new standard in profiling the immune response in clinical or longitudinal studies. Designed to deliver unparalleled coverage and precision, the NULISAseq Inflammation Panel AQ empowers researchers to discover novel signatures of disease progression or therapeutic response with absolute quantitative measurements of over 150 key protein biomarkers from a single sample.With exceptional sensitivity, the NULISAseq Inflammation Panel AQ enables the detection of cytokine levels in both normal and disease states, providing a robust platform for tracking immune changes from baseline or following therapeutic interventions in clinical cohorts. This transformative solution redefines precision in biomarker discovery and clinical research.Key features and benefits of the NULISAseq Inflammation Panel AQ:Unmatched Sensitivity: >99% quantifiability in normal samples allows researchers to detect subtle changes from baseline or after treatment, enabling more accurate monitoring of immune responses.Broad Dynamic Range: Over 9 logs dynamic range allows for simultaneous quantification of both high- and low-abundance proteins from the same sample, ensuring comprehensive data acquisition.High Reproducibility: Achieving a mean coefficient of variation (CV) of <10% ensures consistent and reliable results, even across large clinical studies."The NULISAseq Inflammation Panel AQ is the largest panel for absolute quantification available and represents a major leap forward in precision proteomics," said Yuling Luo, Chairman and CEO of Alamar Biosciences. "Its unprecedented sensitivity and dynamic range provide researchers with the tools to push the boundaries of immune system research, ultimately advancing our understanding of health and disease."The NULISAseq Inflammation Panel AQ is built on Alamar Biosciences' proprietary NULISA™ technology, which combines a patented sequential immunocomplex capture and release mechanism with next generation sequencing to deliver multiplexed, high sensitivity protein analysis. Using just 10μL of sample (25μL input), the panel addresses critical challenges in sample-limited studies, making it ideal for applications in oncology, autoimmune and infectious diseases.For more information about the NULISAseq Inflammation Panel AQ, visit alamarbio.com/inflamAQ.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease

PR Newswire
Jan 8th, 2025
Alamar Biosciences receives $10M for Alzheimer's diagnostics.

The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) has invested $10M in Alamar Biosciences to advance precision medicine in Alzheimer's disease. This is the largest DxA investment to date, supporting the development of Alamar's ARGO™ DX System for in vitro diagnostic tests. The platform aims to create a scalable blood panel for detecting multiple biomarkers, enhancing early detection and personalized treatment in Alzheimer's.

360Dx
Jan 8th, 2025
Alzheimer's Drug Discovery Foundation Invests $10M in Alamar Biosciences

Alzheimer's Drug Discovery Foundation invests $10M in Alamar Biosciences.

PR Newswire
Dec 6th, 2024
Alamar Biosciences Establishes Commercial Presence In Apac Region With First Argo Ht Install At Hong Kong Center For Neurodegenerative Diseases

FREMONT, Calif., Dec. 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). The ARGO HT System along with the NULISA™ Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy

BioSpace
Dec 4th, 2024
ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases

ESYA Labs partners with Alamar Biosciences to advance biomarker detection and diagnostics for Neurological diseases.

PR Newswire
Nov 19th, 2024
Alamar Biosciences Announces Collaboration With The Michael J. Fox Foundation To Advance Parkinson'S Research Through Development Of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker discovery and improve our understanding of Parkinson's disease (PD).  This collaboration aims to address the critical need for robust biological classification of PD and related neurodegenerative diseases. By leveraging Alamar's advanced proteomics platform, the team will develop novel protein assays tailored to identifying key biomarkers associated with neuronal synuclein disease. In addition to partnering on efforts to expand the analytes in the NULISAseq™ CNS Disease Panel 120 to include additional PD-relevant targets, MJFF will also deploy the high-sensitivity NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to analyze roughly 5,000 samples from MJFF's flagship longitudinal study, the Parkinson's Progression Markers Initiative (PPMI). Launched in 2010, PPMI has built the most robust dataset and biosample library ever assembled in Parkinson's research

PR Newswire
Nov 19th, 2024
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ - Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker discovery and improve our understanding of Parkinson's disease (PD).

PRWeb
Nov 15th, 2024
Biomarkers Of Aging Consortium Announces Winners Of Prestigious Biomarkers Of Aging Challenge

The 2024 Biomarkers of Aging Challenge Series has propelled aging research forward, with winning teams developing groundbreaking proteomic and epigenetic predictive models that promise to transform our understanding and assessment of biological aging. Post thisAfter months of rigorous analysis, groundbreaking research, and innovative data modeling, the top honors for Phase 2 and $40,000 have been awarded to Team Kauai, comprised of members Jakob Träuble (University of Cambridge), Korbinian Träuble (Helmholtz Munich), and Raphael Lermer (German Heart Center Munich), for their proteomic predictive model of mortality, which outperformed the epigenetic clock GrimAgeV2.These Phase 2 winners join the winners of Phase 1 of the Challenge, which was focused on prediction of chronological age using epigenetics, and showcased remarkable predictive accuracy, achieving an average error of less than 3 years.1st Place: Julian Reinhard , also known as "DarthVenter," Machine Learning Scientist at Evotec, achieved a final score of 2.45 years age error. Julian received $15,000 USD in awards., also known as "DarthVenter," Machine Learning Scientist at Evotec, achieved a final score of 2.45 years age error. Julian received in awards. 2nd Place: Lucas Paulo de Lima Camillo , Head of Machine Learning at Shift Bioscience, achieved a final score of 2.55 years age error. Lucas received $10,000 USD in awards., Head of Machine Learning at Shift Bioscience, achieved a final score of 2.55 years age error

PR Newswire
Jul 30th, 2024
Alamar Biosciences Establishes European Headquarters And Distribution Center In Milan, Italy

FREMONT, Calif., July 30, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is excited to announce the opening of its European headquarters and distribution center in Milan, Italy. This strategic expansion marks a significant milestone in Alamar Biosciences' commitment to advancing global scientific research through high-sensitivity biomarker solutions and supporting the commercialization of its ARGO™ HT System and NULISA™ Platform.Alamar’s ARGO™ HT System is a fully automated, high-throughput precision proteomics platform at the push of the button. Alamar’s NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.The new European headquarters will serve as the central hub for Alamar Biosciences' operations across Europe, enhancing the company's ability to provide innovative products and exceptional customer service to its growing base of European clients. The distribution center in Milan will ensure efficient and timely delivery of Alamar's comprehensive range of proteomics products, reinforcing the company's dedication to meeting the evolving needs of the global research community."We are thrilled to announce the opening of our European headquarters and distribution center in Milan," said Yuling Luo, Ph.D., Chairman, Founder and CEO of Alamar. "This strategic expansion reflects our ongoing commitment to supporting the scientific community across Europe. Milan's dynamic environment and strategic location will allow us to better serve our customers and accelerate the delivery of our innovative solutions."Key Highlights of the Expansion:Enhanced Customer Service: The establishment of the European headquarters will enable Alamar Biosciences to offer localized support, faster response times, and personalized services to its European customers.The establishment of the European headquarters will enable Alamar Biosciences to offer localized support, faster response times, and personalized services to its European customers

PR Newswire
Jul 26th, 2024
Alamar Biosciences Obtient La Certification Iso 13485, Démontrant Ainsi Son Engagement En Faveur De La Qualité Et De La Sécurité

FREMONT, Californie, 26 juillet 2024 /PRNewswire/ -- Alamar Biosciences, une société qui développe la protéomique de précision pour permettre la détection la plus précoce possible des maladies, annonce aujourd'hui qu'elle a obtenu la certification ISO 13485:2016. Cette norme internationalement reconnue pour les systèmes de gestion de la qualité est spécifique à l'industrie des dispositifs médicaux et témoigne de l'engagement d'Alamar Biosciences à fournir à ses clients des produits et des services de la plus haute qualité.La certification ISO 13485:2016 est une étape cruciale pour Alamar Biosciences, reflétant les processus rigoureux de contrôle de la qualité de la société et l'adhésion aux exigences réglementaires strictes nécessaires à la conception, au développement et à la fabrication de dispositifs médicaux. Cette réussite souligne l'engagement d'Alamar Biosciences en faveur de l'excellence, de la sécurité et de l'amélioration continue.« Nous sommes fiers d'avoir obtenu la certification ISO 13485:2016 à un stade aussi précoce de l'histoire de notre entreprise », a déclaré Yuling Luo, Ph.D., président, fondateur et directeur général d'Alamar. « Cette certification témoigne du travail acharné et du dévouement de toute notre équipe. Elle illustre notre engagement à maintenir les normes de qualité et de sécurité les plus élevées pour nos produits, en veillant à ce que nous répondions aux besoins de nos clients et aux exigences réglementaires de l'industrie des dispositifs médicaux ».Le processus de certification a impliqué une évaluation approfondie du système de gestion de la qualité d'Alamar Biosciences, y compris des évaluations détaillées de ses politiques, procédures et pratiques. Cette certification confirme qu'Alamar Biosciences est conforme à la norme ISO 13485, ce qui constitue une base solide pour la poursuite de sa croissance et de son innovation dans le domaine de la biotechnologie.Alamar Biosciences se consacre aux progrès de la protéomique par le biais d'une recherche et d'un développement innovants

PR Newswire
Jul 26th, 2024
Alamar Biosciences Obtiene La Certificación Iso 13485

- Alamar Biosciences obtiene la certificación ISO 13485, demostrando su compromiso con la calidad y la seguridadFREMONT, Calif., 26 de julio de 2024 /PRNewswire/ -- Alamar Biosciences, una empresa que impulsa la proteómica de precisión para permitir la detección temprana de enfermedades, anuncia hoy que ha obtenido con éxito la certificación ISO 13485:2016. Esta norma reconocida internacionalmente para sistemas de gestión de calidad es específica para la industria de dispositivos médicos y demuestra la dedicación de Alamar Biosciences a proporcionar productos y servicios de la más alta calidad a sus clientes.La certificación ISO 13485:2016 es un hito fundamental para Alamar Biosciences, que refleja los rigurosos procesos de control de calidad de la empresa y el cumplimiento de los estrictos requisitos reglamentarios necesarios para el diseño, desarrollo y fabricación de dispositivos médicos. Este logro subraya el compromiso de Alamar Biosciences con la excelencia, la seguridad y la mejora continua."Estamos orgullosos de haber obtenido la certificación ISO 13485:2016 en un momento tan temprano en la historia de nuestra empresa", afirmó Yuling Luo, Ph.D., presidente, fundador y consejero delegado de Alamar. "Esta certificación es un testimonio del arduo trabajo y la dedicación de todo nuestro equipo. Demuestra nuestro compromiso de mantener los más altos estándares de calidad y seguridad en nuestros productos, garantizando que cumplimos con las necesidades de nuestros clientes y los requisitos reglamentarios de la industria de los dispositivos médicos."El proceso de certificación implicó una evaluación exhaustiva del sistema de gestión de calidad de Alamar Biosciences, que incluyó evaluaciones detalladas de sus políticas, procedimientos y prácticas. La certificación exitosa confirma que Alamar Biosciences opera de conformidad con la norma ISO 13485, lo que proporciona una base sólida para su continuo crecimiento e innovación en el campo de la biotecnología.Alamar Biosciences se dedica a avanzar en el campo de la proteómica a través de la investigación y el desarrollo innovadores

INACTIVE